Regarding cancer subtypes, 12,831 (55%) patients had ER‐positive breast cancer, 15,357 (66%) had HER2‐positive breast cancer, 4744 (20%) had hormone receptor‐positive/HER2‐negative breast cancer and 3065 (13%) had triple‐negative breast cancer [TNBC]. This evidence concerns the gene ERBB2 and cancer.